Tolebrutinib had the most protective effect against disability worsening at 6 months in patients with multiple sclerosis who had a greater number of MRI paramagnetic rim lesions at baseline, data show ...

A post-hoc analysis of phase 3 trials presented at ACTRIMS Forum 2025 suggests that tolebrutinib may be more effective in MS ...

Researchers have found Brukinsa to be a potentially safer alternative for patients with chronic lymphocytic leukemia.

Eli Lilly said the European Medicines Agency's Committee for Medicinal Products for Human Use has recommended expanded approval of its Jaypirca cancer drug in certain patients with chronic lymphocytic ...

March 11, 2025 Barclays 27th Annual Global Healthcare Conference, Miami Beach, FL Fireside chat: March 12, 2025, from ...

Eli Lilly (LLY) and Company announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use has issued a positive ...

TG-1701 is an orally available and covalently bound Bruton’s tyrosine kinase (BTK) inhibitor that exhibits selectivity to BTK in vitro kinase screening; and TG-1801, a bispecific CD47 and CD19 ...

Beyond research, Germain concludes the conversation by providing helpful insights into the biggest challenges in lymphoma ...

How combination therapy with acalabrutinib, a second-generation Bruton’s tyrosine kinase inhibitor, compares with chemoimmunotherapy in patients with previously untreated CLL has been unclear.

Acalabrutinib is a second-generation Bruton’s tyrosine kinase inhibitor with a better safety profile than ibrutinib, including reduced cardiovascular toxic effects. 17 We report here the first ...